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Internationally, there is an increasing focus on quality and sustainability measures oriented to reducing
inefﬁciencies in health provision. The use of assisted reproductive technologies (ART) for older women
represents a case study in this area. This paper analyses the constructions of evidence brought to bear by
ART physicians in the context of deliberative stakeholder engagements (held 2010) around options for
restricting public subsidy of ART in Australia. Physicians participated in two deliberative engagements
during which they were presented with results of a systematic review of ART effectiveness, as well as
ethical and cost analyses. These sessions were part of a broader research program of engagements held
with policymakers, community members and consumers. Physicians deliberated around the data pre-
sented with a view to formulating an informed contribution to policy. The ensuing discussions were
transcribed and subject to discourse analysis. Physicians questioned the evidence presented on the
grounds of ‘currency’, ‘proximity’, ‘selectivity’ and ‘bias’. We outline physicians’ accounts of what should
count as evidence informing ART policy, and how this evidence should be counted. These accounts reﬂect
implicit decisions around both the inclusion of evidence (selection) and the status it is accorded (eval-
uation). Our analysis suggests that participatory policy processes do not represent the simple task of
assessing the quality/effectiveness of a given technology against self-evident criteria. Rather, these
processes involve the negotiation of different orders of evidence (empirical, contextual and anecdotal),
indicating a need for higher-level discussion around ‘what counts and how to count it’ when making
disinvestment decisions.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
In recent years, health reform has increasingly emphasised
measures oriented to supporting safe, effective and cost-effective
care within sustainable health systems. Internationally, a growing
demand for services, coupled with the development of costly new
technologies, has seen healthcare priority-setting become
a complex part of this landscape (Williams & Bryan, 2007). Given
limited resources, it is inevitable that choices be made regarding
‘coverage’ of new technologies (deciding whether their cost will be
subsidised via insurance), and ‘disinvestment’ from established, Australian Catholic Univer-
VIC 3065, Australia. Tel.: þ61
).
-NC-ND license. services deemed to deliver limited health gain for their cost
(Mitton, Patten, Waldner, & Donaldson, 2003).
Mirroring the developing emphasis on ‘evidence-based medi-
cine’, priority-setting processes have been largely informed by the
guiding principles of ‘evidence-based health policy’ (Dobrow, Goel,
& Upshur, 2004). As such they have foregrounded the use of
systematic reviews and health technology assessments, argued to
enable “clinical evidence to be presented as potential solutions to
policy problems” (Williams & Bryan, 2007: p. 2117).
A shift towards stakeholder involvement and deliberation in
decision-making has also been identiﬁed as a feature of modern
health policymaking (Abelson, Giacomini, Lehoux, & Gauvin, 2007),
and has served to inform priority-setting decisions (Russell &
Greenhalgh, 2009). In line with the contemporary evidence focus,
incorporating community and stakeholder perspectives in
decision-making processes has been seen as a means of improving
and legitimating policy directives (Davies, Wetherell, & Barnett,
2006).
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policymaking is argued to increase public ownership of policy
(Scutchﬁeld, Ireson, & Hall, 2004), to address the ‘democratic
deﬁcits’ inherent in traditionally ‘opaque’ processes, and to render
the provision of health services accountable to users as taxpayers,
voters and consumers (Tritter & McCallum, 2006). It is also deemed
to represent a particularly important means of addressing the
inherently complex, ethical nature of priority-setting decisions
(Lomas, Culyer, McCutcheon, McAuley, & Law, 2005).
Participatory and deliberative policy processes may serve to
rebut a central criticism of the trend to evidence-based policy,
namely that this movement depicts policymaking as a “science free
from the inherent messiness of human language, of human inter-
pretation, of human values” (Murray, Holmes, & Rail, 2008: p. 273).
Given that priority-setting processes have been shown to require
far more than cost-effectiveness data to result in locally imple-
mentable decisions (Jenkings & Barber, 2004), deliberative
approaches have emerged as a means of incorporating a range of
data sources (comparative effectiveness research, professional
opinion, the colloquial evidence of stakeholders) into con-
textualised policy guidance (Lomas et al., 2005).
Exactly how clinical evidence and stakeholder perspectives
come together to inform policy directives, however, has increas-
ingly been the focus of qualitative research. Informed by an
understanding of ‘policy as discourse’, these studies have shed light
on the social processes by which health policy ‘problems’ and
‘evidence-based solutions’ are constituted in deliberative contexts
(Russell & Greenhalgh, 2009). Rather than seeing deliberative
engagement as a means of enhancing a pre-existing (usually clin-
ical) evidence base with additional ‘contextual data’, studies within
this ﬁeld treat the notion of evidence per se as a contestable
domain. In deliberative settingswhere evidence is understood to be
‘talked into practice’, analytic attention turns to the social process
of evidence construction and its consequences for health policy.
The present study connects with this critical literature, offering
an examination of the construction of evidence within a policy-
oriented priority-setting deliberation. Speciﬁcally, it provides an
analysis of stakeholders’ (in this case, physicians’) negotiation of
‘what counts’ as evidence within a disinvestment debate. In the
context of deliberative discussions with medical physicians on the
topic of (potential disinvestment from) public subsidy of Assisted
Reproductive Technologies (ART) for older women, we analyse the
strategies by which different orders of evidence were negotiated,
appraised and incorporated into an informed contribution to policy.
In addition, we illustrate the processes by which hierarchies of
evidence, rather than being self-evident, were actively constructed
in the course of this debate.
Disinvestment and the case of ART
The selection of ART as a case study for an analysis of disin-
vestment deliberations was made on a number of grounds. ARTs
possess a number of deﬁning characteristics that meet criteria for
review under proposed disinvestment frameworks (Watt, Elshaug,
Willis, & Hiller, 2011). For example, there exists substantial
temporal and geographic variation in ART service provision, and
differential effectiveness of treatment has been noted across
patient subgroups. In particular, evidence suggests that increasing
maternal age is associated with a decline in positive treatment
outcomes, to the extent that a woman’s age has been described as
the “single most important factor in determining the success of
ART” (Assisted Reproductive Technologies Review Committee,
2006: p. 67).
Australia, via its universal health insurance scheme (Medicare)
provides one of the world’s most generous ART subsidyprogrammes. Yet its funding history suggests that a range of factors
beyond evidence of treatment effectiveness has inﬂuenced the
direction of relevant policy. For example, the “electorally signiﬁ-
cant” (Dill, 2006) force of pro-IVF lobby group opinion has been
identiﬁed as a key factor in the failure of government-mooted
subsidy restrictions, including those seeking to limit subsidies on
the basis of maternal age (Watt et al., 2011). The complexity of the
argumentative terrain around ART subsidy therefore suggested that
deliberation around this topic would offer insights into the social
process of evidence negotiation involved in the construction of
disinvestment policy.
Physicians and ‘what counts’
The analysis presented here is drawn from a broader study that
engaged a range of stakeholders in deliberative discussions around
the public subsidy of ART, focussing onmaternal age and number of
treatment cycles. Informed by the theory of deliberative democracy
(Dryzek, 2000; Fishkin, Luskin, & Jowell, 2000), this research
program aimed to generate an informed and representative
contribution to policy directions around potential reﬁnements to
ART treatment subsidies. This paper analyses transcripts of the
engagements with one particular stakeholder group: physicians
who practise in the area of ART or in the related areas of general
practice, perinatal care or maternal/foetal medicine.
Previous qualitative analyses of priority-setting deliberations
suggest that clinical stakeholders play an important role in the
construction and mobilisation of ‘evidence’ within coverage
debates. As drivers of technology and treatment utilisation, physi-
cians’ involvement in priority-setting activities has been argued to
be imperative (Mitton et al., 2003) and their perspectives afforded
particular persuasive authority within decision-making processes
(Jenkings & Barber, 2004). The ﬁnding that experiential evidence
and personalised clinical anecdotes often serve to ‘trump’ pub-
lished data in informing complex or controversial coverage deci-
sions (Green, 2000) suggests that physicians’ ‘category entitlement’
(Potter, 1996) to knowledge as medical experts renders their
constructions of proof and evidence particularly inﬂuential. For
example, in qualitative studies of healthcare rationing deliberations
involving a range of stakeholders, Jenkings and Barber (2004)
found that decisions were frequently guided by ‘physician excite-
ment’, while Duthie, Trueman, Chancellor, and Liez (1999) found
a repeated deference to doctors for a ‘ﬁnal judgement’ on rationing
directives.
In this study, we analyse the speciﬁc argumentative and
rhetorical strategies mobilised by physicians as they negotiated
constructions of evidence. In particular, we examine how physi-
cians undermined systematic review evidence (presented by the
research team as a means of informing disinvestment deliberation
around the subsidy of ART) while bolstering the objectivity and
facticity of the version they supplied in response.
Methods
Deliberative process
The ﬁrst phase of the project entailed conducting a systematic
review of assisted reproductive technologies (Watt et al., 2011).
This mirrored elements of existing (Australian) Health Technology
Assessment frameworks and policy processes, and was led by
amember of the research team regarded as a pre-eminent expert in
Australian HTA. The review was guided by a protocol appraised by
content experts, and incorporated a range of evidence including
effectiveness data as well as ethical and cost analyses (Carter &
Braunack-Mayer, 2011; Grifﬁths et al., 2010).
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a series of deliberative stakeholder engagements held in South
Australia with groups of ART physicians, non-partisan citizens, ART
consumers and State and Federal health policy advisors respec-
tively. Each stakeholder group attended two engagement sessions
(two ‘rounds’ of engagements spaced a number of weeks apart) in
which they were encouraged to deliberate around the evidence,
and formulate a perspective on their preferred approach to the
provision and subsidy of ART in Australia.
A one-page outline of the data described abovewas circulated to
all participants prior to the ﬁrst engagement, and PowerPoint
summaries of each data source presented by the research team at
the beginning of the session. Deliberation around this evidencewas
then professionally facilitated, while members of the research team
remained in attendance to clarify technical matters as they arose
(rather than acting as participants). In the second round, outputs
from all ﬁrst-round engagements (i.e. the perspectives of each
stakeholder group) were reported to participants and informed
their subsequent deliberations.
The choice to separate stakeholder groups supported partici-
pants to voice partisan opinions freely, without fear of the inter-
actional impact of relative in/expertise (Hendriks, Dryzek &
Hunold, 2007), and allowed an analytic focus on within-group
concerns and constructions. At the same time, the ‘feeding back’
of other groups’ outcomes served the key deliberative goal of
bringing together a range of (potentially contradictory) perspec-
tives (Shapiro, 2003).
While ultimately a research exercise, the process described
above sought to mimic, and enhance with deliberation, existing
policy processes in which the research team has a history of
participation. As such, and given the participation of policy advisors
with health system authority, it follows that physicians, in partic-
ular, treated their involvement as having the potential for material
impact.
Recruitment of ART physicians
Recruitment of the physicians began in a purposive manner. An
introductory email detailing the aims and scope of the project was
sent to the Fertility Society of Australia, the Royal Australian and
New Zealand College of Obstetricians and Gynaecologists, the Royal
Australian College of General Practitioners, the Royal Australasian
College of Physicians and the Australian Medical Association. Each
organisation was invited to send a representative to attend the
engagements, and was offered the opportunity to suggest other
potentially relevant participants. Recruitment then snowballed:
relevant physicians suggested by the original invitees were subse-
quently approached. This method yielded seven participants
(Table 1).
The project received ethics approval from The University of
Adelaide. Participants were assured that their discussions would
remain anonymous when published, and that they were free to
withdraw their participation at any time. Two ﬁrst-round partici-
pants were unable to return in the second round; both conducted
during 2010. Consent to record and transcribe deliberations for
later analysis was obtained from all in attendance.Table 1
Deliberative engagement participant characteristics.
Gender Male 3
Female 4
Clinical area Reproductive medicine specialist 3
Other (e.g. obstetrician, gynaecologist, GP, neonatologist) 4Theoretical perspective and approach to analysis
This paper takes the perspective that policymaking does not
simply represent a process in which self-evident problems are
addressed via the neutral appraisal of technical evidence. Rather, our
approach is to understand policymaking as a process in which the
constitution of policy ‘problems’ and ‘solutions’ is actively negotiated
within a social context. Underpinning this perspective is a broadly
social constructionist epistemology, and a focus on language as the
medium inwhich policy ‘issues’ and ‘evidence’ are constituted.
In line with this framework, we take a synthetic approach to the
analysis of discourse (Wetherell, 1998), attending to the structure of
physicians’ accounts (how they are put together rhetorically so as to
appear factual, credible, etc) as well as their function (how they
serve to position certain kinds or orders of evidence as more or less
compelling). This rhetorical, discursive perspective allows an
analytic focus on the “language, arguments and discourses through
which policy is constructed and enacted, and provides a conceptual
framework for linking decision-making to processes of practical
reasoning” (Russell & Greenhalgh, 2009).
In the ﬁrst analytic phase, transcripts of engagements with ART
physicians were worked through to build up a ﬁle of instances
referencing ‘evidence’ of ART (treatment and cost) effectiveness.
Analysis proceeded to identify the main repetitive patterns evident
across the corpus, attending to:
1. The strategies by which accounts of evidence were constructed
as more or less ‘accurate’.
2. The ‘action orientation’ of these accounts: how they may be
seen to function in supporting a particular construction of
‘evidence’, and the ideological and material consequences of
this construction.
Analysis
In this section we map the strategies by which physicians con-
tested research evidence around the effectiveness of ARTs on the
grounds of ‘currency’, ‘proximity’, ‘selectivity’ and ‘bias’. In turn, we
outline the physicians’ constructions of what should count as
evidence informing ART policy, and how this evidence should be
counted.
A question of evidence
Statistics drawn from the Australian and New Zealand Assisted
Reproduction Database (ANZARD, a registry of the outcomes of all
initiated cycles of ART) formed the basis of the evidence presented
to physicians for their deliberation (see Watt et al., 2011). One
headline statistic from the ANZARD registry reports that, based
upon 2007 data collection (the most recent year available), an
average of 18.8% of initiated cycles of ART culminated in a live birth,
with a maximum 30.1% of initiated cycles generating a live birth for
women aged at or under 30 years and a minimum of 1.0% of cycles
generating a live birth at ages 45 (Wang, Chambers, Dieng, &
Sullivan, 2009). However, the accuracy of this representation of
‘IVF success’ (and its role in informing analysis of the cost-
effectiveness of ART) was questioned by physicians on a number
of related grounds.
Currency
As illustrated in the extracts below, physicians’ accounts of
signiﬁcant recent improvements in IVF outcomes served both to
undermine claims of ‘ineffectiveness’ based upon the ‘maximum
30.1%’ ﬁgure presented by the research team, and to question the
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Extract 1
Physician 1: What year were those stats? I think you’d probably
ﬁnd those sorts of stats have changed a fair bit in the last couple
of years.
Research team member: They are from the early 2000s. .
Physician 1: The pregnancy rates in that group would have
doubled during that time.
Extract 2
Research teammember 1: The ANZARD data, it’s (.) reporting
still in the 30% not the 50%, the pregnancy rate.
Physician 1: That is 30% overall for all cycles. We are talking
about 50% under 38.
Research team member 2: [Referring back to the data she is
quoting] Less than 35 years pregnancy ANZARD 2004 to 2007.
Physician 1: That is really old.
In Extract 1 above, Physician 1’s ‘insider knowledge’ of recent
improvements in IVF outcomes serves to question the legitimacy of
debate based upon outcomes that have since “doubled”e a relative
quantiﬁer that bolsters her claim of ‘signiﬁcant change’.
Similarly, in Extract 2, Physician 1 questions the validity of using
ANZARD data on the grounds that it is “really old”. In turn, she
privileges her own representation of IVF outcomes (“50%” for
“women under 38”) over those derived from the database.
In the context of disinvestment debates, such emphasis on
‘current’dataewhile understandable givenphysicians’professional
interests and day-to-day vantage point e represents a potential
barrier to doctors’ engagement in the process of policy develop-
ment. Indeed, engagement in policy debates requires tolerance of
some level of ‘data lag’. Acknowledgement of the provisional,
defeasible nature of medical evidence underpins disinvestment
discussions across the board, and represents an important step in
moving debate from issues of ‘data’ to more abstract notions of
allocative efﬁciency. At the same time, however, this discussion
suggests that physicians’ input represents a means of ensuring that
policy is grounded in ‘meaningful evidence’ e a particularly
important contribution in areas of rapid technological change.Proximity
Linked to questions of currency were questions of ‘proximity’ e
the notion that physicians are privy to more recent, and richer,
outcomes data by dint of their insider knowledge.
Extract 3
Physician 2: The total data is published late.We do havemonth-
to-month data.
Extract 4
Physician 2: We know [the data on effectiveness]. I’m sure [Dr
X] has her numbers in her head. I know the most recent [Clinic
X] numbers are higher than they were a year ago.
In the extracts above, Physician 2 presents an account of
physicians’ nuanced and up-to-date awareness of ART outcomes.
While Physician 2’s account of improved outcomes is imprecise
(the numbers are simply described as “higher than theywere a year
ago”), it provides enough information to sustain an argument of
growth that casts doubt on the ‘ofﬁcial’ statistics.
The accounts presented here have implications for disinvest-
ment debates in that they serve to question the validity ofpolicymakers’ use of the ANZARD dataset on the grounds of both
currency and status. In contrast to the perspective presented
elsewhere in the engagements that ANZARD reporting require-
ments make ART a disinvestment “target . because there’s
evidence to use” (Physician 2), accounts prioritising doctors’ ‘data-
proximity’ reclaim physicians’ prime position as evidence arbiters.
Indeed, in the extracts above, claims of absolute understanding
and consensus (“I know”, “We know”), alongside indications of
intimate statistical knowledge (“I’m sure Dr X has her numbers in
her head”), build a possessive account of the data. Such accounts
are in contrast to those identiﬁed in Jenkings and Barber’s (2004)
study of evidence negotiation in hospital new drug committees, in
which physicians (and others) took pains to quote ‘ofﬁcial statis-
tics’ in order to present themselves as ‘objective’ in the context of
data appraisal. Indeed, here, it is physicians’ subjectivity that is
taken to bolster the credibility of their version of appropriate
evidence.
In a policy context necessarily reliant on population statistics, an
emphasis on ‘data proximity’ may preclude physicians’ engage-
ment with bigger-picture disinvestment discussions that may take
ofﬁcial data records ‘as read’. However, it could equally be seen that
physicians’ access to ‘data in context’ sees them uniquely posi-
tioned to add important nuance to policymakers’ interpretations of
‘ofﬁcial’ evidence repositories.Selectivity
Physicians also contested the evidence provided by the research
team (particularly that relating to the analysis of ART’s cost-
effectiveness) on the grounds that analytic selectivity could be
seen to have coloured the data presented.
In particular, physicians criticised what they saw as the omission
of reference to contextual factors impacting upon ART outcomes.
These factors, deemed to complicate outcomes data and subse-
quent cost analyses, included changes to Medicare rebates (the
proportion of the treatment cost covered by Medicare, Australia’s
universal public health insurance) and the lack of funding for egg
donation.
Extract 5
Physician 2: You bring in the confounding factors of minimal
funding being applied to egg donationwhich pushes those older
women to keep trying relentlessly for their own eggs.
Extract 6
Physician 1: The evidence presented is using Medicare data
based on the Medicare funding from last year which is already
signiﬁcantly different this year because of, effectively, the
reduction of public funding that occurred with the changes to
the Extended Medicare Safety Net*.
(*The EMSN represents a ceiling on the out-of-pocket costs an
individual or family can incur through their use of Medicare out-of-
hospital services. Once the threshold is reached, the EMSN pays 80%
of the out-of-pocket costs for Medicare-related services for the rest
of the calendar year.)
In each of the extracts above, important social and economic
factors are depicted as “confounding” the ANZARD-derived
measurement of treatment outcomes. As these accounts suggest,
ART success rates are potentially impeded by the prohibitive cost of
egg donation (without it, older women’s numerous ART attempts
may reduce per-cycle rates of success), and by subsidy restrictions
(perhaps limiting the access of couples who might otherwise have
found success in subsequent cycle attempts).
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considering ART outcomes within their social and economic loca-
tion, these accounts appear to privilege evidence of ART’s potential
rates of success in a ‘perfect world’. Although advocating the
inclusion of contextual factors in success rate calculations
(commensurate with an effectiveness model oriented to ‘outcomes
under real-world conditions’), the accounts present such factors as
obscuring the ‘real’ success of ART treatment programs that would
be enjoyed ‘if conditions were ideal’.
It may be appropriate that doctors attend to the speciﬁc issue of
potential treatment outcomes rather than taking a broader view:
their vantage point naturally foregrounds treatment ‘possibilities’
for individual patients rather than population-level outcomes.
However, such an evidentiary lens is at odds with a perspective
appraising ART’s effectiveness-in-context (the implicit basis of
a policy-orienteddiscussion). Ultimately, in the extracts above,what
appears to be an empirical debate about the accuracy of evidence
(what are the ‘real’ outcomes of ART?) may instead be seen as an
ontological debate about the status of different kinds of evidence
(What counts as evidence of ARTeffectiveness:whatwe see, orwhat
we could see under optimum conditions? What are our grounds for
deciding where ‘accuracy’ and ‘relevant context’ meet?).
As people who see ﬁrsthand the important beneﬁts of their
treatments, and the potential for improved outcomes if external
factors are conducive, it is to be expected that physicians will
present the best possible account of ART success. Moreover, in
a disinvestment context, it seems natural that physicians will
defend against potential subsidy restrictions that will impact upon
them both professionally and materially. What is important,
however, is that these allegiances, and framings of appropriate
evidence (foregrounding ideal/potential treatment outcomes, or
effectiveness-in-context), are made explicit within a participatory
policy process. Likewise, as part of an enhanced disinvestment
evidence base incorporating stakeholder perspectives, openness
about physicians’ ‘stake’ (Wetherell, 1998) could serve to con-
textualise their offering as a vital means of adding nuance to the
received statistical wisdom, and to position their contribution as
generative as opposed to defensive.
Bias
Linked to questions of selectivity was the more explicit claim of
researcher ‘bias’.
Extract 7
Physician 3: I think the evidence that was presented was very
biased . I think it was a particular idea that they wanted to
push.We have the idea of what actually happens in ART.
Research team leader: Could I backtrack on that evidence
question?
. In what way was that evidence biased, given we followed
a systematic review protocol that we had some external input
into? That’s the steps. . Did we ask the wrong questions?
Physician 1: Yes.
In this section of talk, the evidence presented by the research
team was questioned on the grounds that the outcomes were
perceived to reﬂect a preconceived agenda rather than an impartial
appraisal of evidence. The exchange outlined here illustrates two
levels of complexity when it comes to policy processes in which
stakeholders are engaged in evidence appraisal.
Stakeholders’ perspectives may prime them to treat certain
realms of evidence as particularly salient or, indeed, as ‘obvious’. In
turn, policy discussions grounded in a presentation of evidence that
minimises or excludes these concerns may be critiqued not only asinaccurate but, potentially, as ‘wilfully’ so. The validity of evidence
presented may therefore be questioned on the grounds of data
accuracy and/or the credibility (absence of vested interest) of the
sources by whom the data are produced e claims that may be
elided into the generic critique that the data are simply “wrong”.
The argument outlined here raises a criticism often levelled at
deliberative processes: that the presentation of ‘evidence’ neces-
sarily involves selections that work to frame resultant discussions
(Walmsley, 2009). In response, it could be argued that this situation
simply mimics real-world policy processes in which (often) non-
expert political advisors are presented with a speciﬁc range of
data to inform their decisions. Through this lens, the methodology
of the current project e seeking to enhance a traditional evidence
base for policy through the incorporation of stakeholder perspec-
tivese goes someway towards counterbalancing issues of evidence
selectivity.
Issues of data selection and evaluation may apply equally to the
contributions of stakeholders themselves. In each of the extracts
addressed thus far, physicians’ critiques of the research team’s
data also comprised selections (recent data was privileged over
retrospective ﬁgures; excluding contextual factors was con-
structed as undermining the validity of calculations of ART
success) and evaluations (the credibility of data sources was held
to be diminished by ‘vested interest’ and bolstered by ‘data
proximity’).
We can also see from the extracts that physicians did not simply
critique the research team’s evidence on the grounds of what data
was counted, but also how it was counted. For example, in Extract 7,
the implicit contention that accuracy calculations should fore-
ground the potential of the treatment e perceived efﬁcacy under
optimal policy and clinical conditions e rather than simply
attending to the real-world effectiveness-in-practice as had been
the researchers’ perspective.
In the context of disinvestment decisions, different con-
ceptualisations of evidencee questions ofwhat and how to count e
are not without effect. We now demonstrate this through an
analysis of the alternative accounts of ART’s (cost-) effectiveness
proffered by the physicians with whom we engaged.
What to count: physicians’ perspectives
Throughout the engagements, physicians argued that a range of
factors not considered by the research team must be included in
any valid appraisal of the value of ART.
Alternative treatment costs
Physicians noted the potential for alternative costs, or unin-
tended consequences, to replace those incurred throughout the
course of ART if access to such treatment was restricted.
Extract 8
Physician 4: If IVF was not as readily available and in particular
if it was more poorly funded, a lot more couples would have
laparoscopies . which unfortunately can be futile. .[T]he
number of laparoscopies that I personally do has dropped off
a lot since IVF has become more successful and more accessible,
and laparoscopic surgery is very expensive.
In this extract, the cost of laparoscopies e presented as
a consequence of IVF subsidy restriction e is depicted as an
essential component of any valid calculation of the sustainability of
ART when such technologies are viewed ‘in context’. Implicit in this
account is a conceptualisation of the evidence required for disin-
vestment discussions as only appropriate/useful if it measures the
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‘the entire system-borne cost of intervention/s in this area’, rather
than that of one speciﬁc technology. As evident in the extract above,
this perspective is reliant upon physicians’ anecdotal data around
patient behaviour e a different order of evidence than that tradi-
tionally informing cost-effectiveness analyses.
Alternative costs borne by individuals were also raised as
a requisite component of ART cost analyses, once again expanding
the terrain of ‘relevant evidence’ required to inform an analysis of
cost-effectiveness.
Extract 9
Physician 4: You need to compare the cost of a couple
conceiving with IVF with the cost of other sorts of treatments
they would be looking at if IVF wasn’t funded, not compared to
a home conception which is zero.
Physician 2: The costs would never get measured: naturopathic
costs, acupuncture costs, Chinese medicine costs, herbs,
psychological interventions.
Here, comparisons between the cost of home conception and
that of IVF are constructed as both unfair and misleading. In
response, Physician 2 widens the remit of the cost-effectiveness
analysis to include the patient-borne cost of alternative and
psychological treatments deemed likely to result from ART subsidy
restrictions.Cost of restrictions: health of mother and baby
Physicians also raised concerns about the hidden costs of ART
subsidy restrictions in terms of the possible adverse health
outcomes for mother and baby if ‘alternative measures’ are taken.
That is, they argued that subsidy restrictions would reduce the
affordability of multiple cycles of IVF, thereby increasing the pres-
sure on physicians to extract more eggs, and replace multiple
embryos, in a bid for early-cycle success. The outcome of this
patient demand, as the physicians saw it, would be increased rates
of both ovarian hyperstimulation and multiple births (resulting
from pressure to transfer multiple embryos).
Extract 10
Physician 4: I know of the costs of the alternative often futile
surgeries that will be done. but nothing [is said] about all the
costs that we all know that would suddenly occur because of
multiple births and increase in ovarian hyperstimulation.
Extract 11
Physician 5: If you are replacing multiple embryos and have
twins or higher multiple pregnancies then they automatically
become far more complicated, you have a far greater risk.
Within these accounts, ovarian hyperstimulation and risky
multiple births are constructed as inevitable and costly conse-
quences of IVF subsidy restrictions. This narrative suggests a causal
relationship between subsidy restrictions and the potential for
these adverse outcomes. Yet the notion that physicians have
considerable professional agency in guiding and regulating these
circumstances (i.e. practising ‘in the best interests of the patient’) is
absented in an account that implicitly depicts patient persuasion as
an ‘insurmountable’ pressure.
Interestingly, in the context of a policy-oriented discussion, the
construction of these inevitable adverse outcomes serves to
bolster the argument in favour of retaining IVF subsidies, rather
than to support calls for increased regulation of IVF treatment
processes.Emotional costs
Extract 12
Physician 2: [T]here’s very little emphasis given to looking at the
evidence of the psychological burden of childlessness, the
psychological burden of shame and blame and secrecy around
infertility, and perhaps a measure of success with an unsuccessful
IVF journey for awomanmay be [that] she canmove on to a life of
childlessness feelingas if theyhavemadeasmucheffortas theycan.
Extract 13
Physician 2: I’m talking about childless womenwhowould have
otherwise had a chance and didn’t because of technology not
being available, just because they don’t talk about it doesn’t
mean there isn’t this big elephant in the room of hurt and
sadness and tragedy. I don’t know it’s possible to measure that.
The notion that emotional costs must be factored in to analyses
was a ﬁnal critique raised by the physicians. In these extracts,
Physician 2 once again expands traditional components of cost-
effectiveness calculations to encompass the psychological burden
of childlessness potentially alleviated by access to IVF. In these
accounts, the cost of being denied access to reproductive technology
is simultaneously constructed as measurable (closure in an unsuc-
cessful IVF journey is depicted as a ‘measure of success’) and
immeasurable (Physician 2 doesn’t “know if it’s possible tomeasure”
the detrimental effects of not being given “a chance”). Thus the
intangible beneﬁts of IVF are rendered speciﬁc enough to sustain
a moral argument (providing closure is surely a signiﬁcant measure
of success), yet vague enough to avoid critical scrutiny (it is difﬁcult
to imagine how closure may be deﬁned, let alone measured and
subject to systematic review). Interestingly, the incorporation of
psychological health outcomes in these accounts focuses solely on
the positive role that may be played by IVF: no mention is made of
the potential for psychological harm (and options for its measure-
ment) that could result from multiple failed attempts.
As these examples show, different conceptualisations of what
should be counted have signiﬁcant differential effects on the
calculation of the value of IVF subsidies. Likewise, alternative
conceptualisations of how such data should be counted impact
upon the sustainability verdict.How to count: physicians’ perspectives
A range of implicit decisions around how data should be eval-
uated underpinned physicians’ accounts of the sustainability of
ART. For example, physicians suggested that evidence of ART’s cost-
effectiveness should be assessed in relative (rather than absolute)
terms: that is, assessed in relation to the cost-effectiveness of other
treatments, the notion of ‘waste’ constructed as only possible to
evaluate in relation to other areas of health provision.
Extract 14
Physician 6: If you ask them to cut medical services that are
utterly useless, for example putting people 75 years or more on
ICU, they will not even dare to go there. We all know that’s
a total waste of money, that costs far exceed any fertility treat-
ment but they will never touch that because they are not brave,
they are politicians.
Extract 15
Physician 3: It seems like there’s a universal agreement that
$30,000 approximately for a live birth per cycle, that relative to
other modalities of medicine that is good value for money.
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money we have in healthcare.
Similarly doctors argued that any calculation of the sustain-
ability of IVF should interpret cost-effectiveness data in terms of
the ‘return on investment’ of such technology when compared
to other areas of medicine.
Extract 16
Physician 4: You need to look at return on investment. They can
payand look after us in the future. If it’s [$]8000 to create a life, as
long as they are healthy which most of are, unless we have to
start putting two embryos back, we have a tax payer for 40 years.
In Extract 16, physicians may be seen to apply a cost-utility
frame, inferring value for money via what is arguably a version of
the ‘cost per quality adjusted life year (QALY) gained’ from the live
births generated by ARTs. While there is considerable contention
around the applicability of QALYs in the context of ART (for
example, Devlin & Parkin, 2003 argue that additional lives are not
‘improvements in health’), it is signiﬁcant to note that the physician
here appears to borrow from, while subverting, the language of
‘cost-effectiveness’. Notions of ‘efﬁciency’ and ‘return’ serve in this
extract to assess the relative value of technologies in terms of
‘taxpayer payoff’, a deﬁnitional choice that has signiﬁcant impli-
cations in building an alternative account of ‘value’.
We conclude with a data extract illustrating the way in which
contest over evidence construction was played out in context, with
ideological (and, potentially, material) effect.
Extract 17
Physician 4: [T]he poor prognosis and futile [ones] they are such
a tiny little proportion of the people we treat where we’re
generally looking at a 50% pregnancy rate per cycle for the
majority, the large group of women we treat. The return on
investment for that is amazing. You generally do get a healthy
child if you put only one embryo back in ..
Physician 2: You can’t assess if someone is in that group that has
a 50% chance of success until they’ve done three or four cycles.
Physician 4: For someone who gets pregnant on their fourth
cycle, may still have a good 50% chance of pregnancy. It
randomly takes them e you know, a throw of the dice is four
cycles for them.
Physician 2: If you’re not pregnant by four then maybe you fall
into the group that doesn’t have the 50% chance. This is dis-
regarding the ones we know from the starting point they are not
50[%]. The vast majority falls into the group who should have
about a 50% chance of success.
Physician 4: Whenmost good units in Australia have got overall
pregnancy rates, and that is putting the poor prognoses in with
the tiny number of futile ones, overall per cycle of 35e40% with
live birth rates of 35%. These people that public economists
could argue we are throwing money away for is a tiny propor-
tion of our overall people going through.
Physician 2: Smaller amount of money than the election
advertising bill.
In the ﬁrst paragraph of Extract 17, an account of ART treatment
effectiveness is bolstered in a number of related ways. Firstly, and
perhaps most signiﬁcantly, is the selection of pregnancy rate per
cycle as the key measure of treatment success (‘we’re generally
looking at a 50% pregnancy rate per cycle’). As an indicator of
outcomes, ‘pregnancy rate per cycle’ maximises treatment success
as it divides the total number of pregnancy outcomes by the total
number of cycles undertaken by all women. This calculation doesnot include unsuccessful patients who drop out between cycles,
whereas such attrition would be included in a calculation of the
‘pregnancy rate of patients who commence IVF treatment’. Preg-
nancy rate per cycle also includes the outcomes of later-rank cycles,
in which patients would have had the beneﬁt of ongoing inter-
ventions aimed at increasing their chance of conception.
Further support for a maximised presentation of success is
achieved in the extract by attaching a population pregnancy rate (“a
50% pregnancy rate per cycle”) to individual patients (“a 50%
pregnancy rate per cycle for the majority, the large group of women
we treat”). It may be seen that this account conﬂates different levels
of explanation: a success rate calculation based on the total number
of pregnancies resulting from the total number of cycles under-
taken by all women is presented as though it represents an indi-
vidual woman’s likelihood of success.
Additional maximisation may then be seen to underpin the 50%
pregnancy rate outlined by Physician 4. Rather than presenting the
percentage pregnancy outcomes of all women who attend for IVF,
the calculation on which the claim is built divides the number of
pregnancy outcomes by a reduced patient sample e the 50%
success rate is attributed to the “majority of women that we treat”.
Ultimately, the account presented here suggests that approximately
half of all womenwho undergo a cycle of IVF will become pregnant,
yet relies upon a calculation from which a group of unsuccessful
women (those labelled “poor prognosis” or “futile”) have been
removed (yet unsuccessfully treated). In turn, the statement “you
generally do get a healthy child” (suggesting a ‘better than chance’
outcome and shifting the outcome measure to ‘live birth’) supports
the claim that IVF represents an “amazing” return on “investment”.
Throughout this extract, a range of descriptive selections are
used to underpin an account of IVF success and value. These
selections include a shift from population statistics to individual
likelihood predictions, as well as an adjusted patient denominator
being employed to maximise depictions of success. We also note
a contrasting use of absolute ﬁgures (“50%”) and the use of non-
numerical relational descriptors (successful patients are described
as the “large” “majority”, while the group of those who are
unsuccessful are minimised as “tiny”), as well as a shift between
outcomes variously deﬁned as “pregnancy”, “a healthy child” (an
outcome notably absent from ofﬁcial data repositories), or themore
vaguely described “success”.
Within disinvestment deliberations, such selections, catego-
risations and resultant evaluations provide support for speciﬁc
funding outcomes and interpretations of value. For example,
Physician 2’s apparently technical claim that “someone who gets
pregnant on their fourth cycle, may still have a good 50% chance of
pregnancy. It randomly takes them e you know, a throw of the dice
is four cycles for them” can be seen to support the moral argument
in favour of giving all women aminimum of the four cycles it might
“randomly take them” to conceive within this process. The
presentation of four cycles as being necessary for an authentic
assessment of their chances conﬂates the notion of ‘chance’ (what
is random) with the notion of ‘giving them a chance’ (an ethical
concern).
Likewise, Physician 4’s ostensibly factual claim that the “people
that public economists could argue we are throwing money away
for is a tiny proportion of our overall people going through”
supports an evaluative comparison against the cost of election
advertising. Physician 2’s statement that unsuccessful IVF treat-
ments represent a “smaller amount of money than the election
advertising bill” brings to bear not only a ﬁscal comparison, but
a moral judgement about the relative expenditure: how can we
think about restricting this important/effective procedure the costs
of which are exceeded by other (morally questionable) outlays?
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Our analysis illustrates that engagement with physicians around
a disinvestment question did not serve simply to append objective
outcomes data with ‘clinical judgement’ to generate a ‘more accu-
rate’ assessment of ART effectiveness that might inform relevant
policy. Instead, physicians’ constructions of legitimate evidence
served to question and reframe both the terms of debate (whether
ART should even be considered as a disinvestment candidate) and
means of appraisal (what should be included/excluded from deﬁ-
nitions of ‘effectiveness’). Our illustration of the rhetorical, argu-
mentative nature of physicians’ contributions afﬁrms the
importance of opening the ‘black box’ of health policy decision-
making particularly in contentious areas where stakeholder
contributions are vital, yet processes for incorporating them remain
unclear (Williams & Bryan, 2007).
As we have outlined, physicians’ critique of the research team’s
data on the basis of currency, proximity, selectivity and bias
undermined the validity of identifying ART as a disinvestment
candidate. Given the authority afforded doctors within priority-
setting deliberations (Duthie et al., 1999), the mobilisation of these
strategies is signiﬁcant, serving to elevate physicians’ own account
of evidence (based upon ‘current, ﬁrst-hand’ experience) above that
derived from clinical literature. Physicians’ inﬂuence in this regard,
and the notion that any priority-setting activity may be “doomed at
the outset” (Mitton et al., 2003: p. 1659) without their engagement,
appears to see them favoured bya deliberative evidence asymmetry
within such processes. Indeed, we suggest that physicians’ critiques
have the potential to forestall disinvestment debates on the grounds
of questions of evidence e a potentially problematic ﬁnding when
one considers physicians’ stake in priority-setting decisions that
stand to impact upon them both professionally and ﬁnancially.
While it may be deemed quite legitimate for physicians to be
afforded a particular ‘category entitlement’ (Potter, 1996) to
knowledge of clinical data, the role of their contribution to the
ethical aspect of disinvestment debates is perhaps more conten-
tious. While McKie, Shrimpton, Hurworth, Bell, and Richardson
(2008) found that consumers desire a distinction to be made
between clinical and ethical expertise within health priority-
setting debates, these aspects may be discursively elided in delib-
erative contexts. As our analysis illustrated, physicians’ accounts of
ART treatment effectiveness blurred the line between clinical data
(evidence of outcomes) and assessments of worth (arguably ethical
concerns) within an ostensibly ‘neutral’ appraisal of evidence. The
notion that physicians’ moral arguments could be afforded the
same credence as their clinical contributions may be of concern
where health policymaking deliberations seek to include, and
balance, a range of stakeholder perspectives on economically and
socially complex issues.
Conclusion
A central criticism of deliberative democratic methods within
policy contexts is the notion that outcomes are inevitably shaped
by the evidence informing discussions (Russell & Greenhalgh,
2009). Interpretations of evidence, and subsequent deliberative
outputs (Walmsley, 2009), are necessarily ‘framed’ by the selec-
tions and evaluations that underpinwhat is often represented as an
‘objective’ evidence base. Our analysis suggests that such concerns
are legitimate. As we indicate, both policy ‘problems’ and ‘solutions’
rely upon the selection and interpretation of evidence, and deci-
sions in this regard are inexorably linked to the social context in
which they are negotiated.
We argue that the difﬁculty of negotiating questions of
evidence should not be taken as cause to abandon engaged,deliberative processes in the context of disinvestment decision-
making. On the contrary: the accounts of physicians described
above add vital nuance to debate around disinvestment options,
their contribution highlighting an important perspective and
supporting accountable decision-making. For example, physi-
cians’ capacity to catalogue potential ‘unintended conse-
quences’ represents a valuable contribution when modelling the
likely impact of any disinvestment initiative. Similarly, their
pivotal role in implementing policy outcomes suggests the
importance of facilitating physicians’ buy-in at key decision-
making junctures.
Ultimately, however, our analysis indicates that dispute around
what constitutes ‘appropriate evidence’ in a disinvestment context
has the potential to forestall true deliberation in this domain. For
this reason, we argue that stakeholder-engaged deliberative
processes might usefully begin with an explicit, meta-level
discussion around evidence and ‘what counts’. Our analysis
suggests that once a technology or practice has been identiﬁed for
disinvestment consideration, consensus from a range of stake-
holders (whose interests and perspectives are explicitly acknowl-
edged and appreciated for the value they add) around what can,
does and should constitute evidence has the potential to support
later, genuine, deliberation around funding policy.Acknowledgements
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